Shire sues US firm over epilepsy drug
Thursday 15 January 2004
Shire Pharmaceuticals has launched a lawsuit against Nostrum Pharmaceuticals after it made public plans to launch a similar version of Shire's epilepsy drug Carbatrol.
Nostrum, a privately owned company based in New Jersey, filed a new drug application for a generic version of the 300mg dosage strength of Carbatrol.
Shire, which launched its Carbatrol drug in 1998, said it had served Nostrum with a complaint for patent infringement but would not go into details. A spokeswoman said its patents on the drug - which has made about $164m of sales since its launch - did not expire until 2016. "Our lawyers have looked at the dossier [from Nostrum that has been filed with the US Food & Drug Administration] and believe it infringes patents," she said.
The move is not a great surprise, however, since the FDA announced last summer that an unnamed drug manufacturer had asked it to approve a copycat version of Shire's epilepsy treatment.
Carbatrol is one of Shire's main drugs and produced sales of $11.6m in the third quarter of last year. The company estimates it has about a 40 per cent market share.
The spokeswoman also said yesterday that the filing centred only on the 300mg strength of the drug and did not affect its 100mg or its 200mg products.
The 300mg strength, she said, made up about half the total sales Shire has so far recorded from Carbatrol.
The company's response to Nostrum's filing triggers a 30-month stay of approval - meaning the earliest date a generic version of the drug could be launched, if cleared by the court, is January 2006.
Shire's biggest selling drug is its hyperactivity drug Adderall XR, which accounts for about half of its sales. It is also battling to prevent generic versions of that drug hitting the market. At the end of last year, it announced it was suing the US drug maker Impax, which signalled it was developing a copy of Adderall XR. It has already launched proceedings against Barr, another US company developing generic Adderall.
- 1 Is Gideon Levy the most hated man in Israel or just the most heroic?
- 2 Students offered grants if they tweet pro-Israeli propaganda
- 3 Satellite full of sexually experimental geckos adrift in space, Russia loses control of mission
- 4 Exclusive: Cameron’s ‘Big Society’ in tatters as charity watchdog launches investigation into claims of Government funding misuse
- 5 Israel has discovered that it's no longer so easy to get away with murder in the age of social media
MH17 crash: Investigators discover more human remains and 'huge section of plane'
Susan Sarandon on David Bowie romance: 'He's worth idolising'
Students offered grants if they tweet pro-Israeli propaganda
A day in the life of Vladimir Putin: The dictator in his labyrinth
Exclusive: Cameron’s ‘Big Society’ in tatters as charity watchdog launches investigation into claims of Government funding misuse
The 'scroungers’ fight back: The welfare claimants battling to alter stereotypes
Arizona execution lasts two hours as killer Joseph Wood left 'snorting and gasping' for air
Malaysia Airlines MH17 crash: Ukrainian military jet was flying close to passenger plane before it was shot down, says Russian officer
Malaysia Airlines MH17 crash: Massive rise in sale of British arms to Russia
Malaysia Airlines MH17 crash: victims’ bodies bundled in black bags and loaded onto trains
John Barrowman praised for Commonwealth Games opening ceremony gay kiss
iJobs Money & Business
£600 - £650 per day: Orgtel: Conduct Risk Liaison Manager - Banking - London -...
£18000 - £23000 per annum + Comission: SThree: SThree, International Recruitme...
£280 - £300 per day + competitive: Orgtel: Test Analyst, Edinburgh, Credit Ris...
£20000 - £25000 per annum + OTE £40,000: SThree: SThree Group have been well e...